In the early 1960s, Dr. Arnold Kadish developed the first insulin pump, which was the size of a Marine backpack.1  Over the years, insulin pumps have become much more refined and have decreased in bulk to the size and weight of a small pager. Insulin pump therapy, also known as continuous subcutaneous insulin infusion, is no longer seen as experimental and controversial, but rather is viewed as an acceptable alternative to multiple daily injection (MDI) therapy in the management of insulin-dependent diabetes2  (Table 1).3 

The insulin pump is an electromechanical device that mimics the body's natural insulin secretion from pancreatic β-cells by subcutaneously delivering rapid-acting insulin both at preset continuous basal rates and in extra bolus doses at mealtimes on demand.4  Insulin pumps allow for up to 24 different hourly basal rates in a 24-hour period. For bolus doses, pump users input their current blood glucose level and the number of carbohydrates they will consume, and the pump customizes their dose based on insulin currently on board (i.e., the remaining active insulin from the previous dose), their individualized insulin-to-carbohydrate ratio, and their individualized insulin sensitivity factor (i.e., their expected drop in blood glucose from 1 unit of insulin).1,5  Thus, insulin pumps are able to deliver insulin in a more physiological manner than other injection-based insulin regimens.5 

In the late 1970s, results of the first human trials of insulin pump therapy were published. This was followed by numerous additional studies comparing insulin pump therapy to traditional MDI regimens with regard to long-term glycemic control and minimization of hypoglycemia.611  Then, in 1993, the Diabetes Control and Complications Trial12  confirmed the importance of intensive glycemic control using either insulin pump therapy or an MDI regimen along with frequent self-monitoring of blood glucose (SMBG).

In patients with type 1 diabetes, pump therapy has been shown to limit excess weight gain, reduce the frequency of severe hypoglycemia, and lower A1C levels.13  Pump therapy is also a therapeutic alternative for insulin-requiring patients with type 2 diabetes, especially those who require large amounts of insulin, have severe insulin resistance, and have poor glycemic control,14,15  and has been observed to reduce insulin requirements and lower A1C levels in patients with type 2 diabetes.14,16  Compared to MDI, insulin pump therapy allows for greater flexibility with timing of meals, reduces the risk of exercise-induced hypoglycemia, allows for overnight glycemic control, and gives patients greater ability to manage their own diabetes.13 

Insulin pumps consist of a reservoir, a pump, and an infusion set. The reservoir, which is similar to a syringe, holds a 2- to 3-day supply of insulin and is placed into the battery-powered pump. The infusion set consists of tubing that connects the reservoir to a cannula (i.e., a tiny tube to deliver insulin subcutaneously) and transports the insulin from pump to patient. A small piece of adhesive holds the cannula in place at the insertion site.1 The needle of the infusion set can be inserted into the abdomen, upper thigh, or upper arm. The infusion set and reservoir must be changed every 2–3 days.

Table 1.

Comparison of Current Insulin Pumps3 

Comparison of Current Insulin Pumps3
Comparison of Current Insulin Pumps3

The indications for insulin pump therapy include inadequate glycemic control (defined as an A1C > 7%, the dawn phenomenon [early-morning increase in blood glucose], and marked variability in glucose from day to day); hypoglycemic episodes requiring assistance or hypoglycemia unawareness; the need for flexibility in lifestyle; and pregnancy or intention to become pregnant.13,17  All candidates should have the willingness and ability to learn how to use an insulin pump and to perform SMBG multiple times per day.1,4 

Patients with significant psychological problems such as psychosis or severe depression are not appropriate candidates.4  Ongoing education, motivation, and psychological support are required for patients to succeed with insulin pump therapy. Patient education should include the principles of basal-bolus insulin therapy, sick-day management, carbohydrate counting, glucagon administration, site preparation and infection prevention, prevention and treatment of hypo- and hyperglycemia, and insulin adjustments for exercise.17  The most crucial factors for patient success are patients' willingness to perform frequent SMBG and sufficient ongoing clinical support.17 

The Longstreet Clinic (TLC) is a regional multidisciplinary physician practice. The Internal Medicine (IM) and Family Medicine (FM) departments are located in Gainesville and Oakwood (Hall County), Ga. Hall County is located in north-east Georgia 50 miles northeast of Atlanta. The population of Hall County is ~ 187,700.

Within the IM and FM departments, the Diabetes Education and Medical Nutritional Therapy department provides diabetes education and management services for patients with diabetes. Within this department, there is an interdisciplinary team of certified diabetes educators (CDEs) composed of a registered nurse (team leader), a registered dietitian, and a pharmacist, all of whom are certified insulin pump trainers. The department offers various services, including individual and group diabetes education, gestational diabetes education and management, pediatric obesity education classes, and insulin pump therapy education and management.

Approximately 20% of all IM and FM patients have diabetes. Forty-seven percent of these diabetes patients are on insulin therapy, of which 3% use an insulin pump. For patients on insulin pump therapy, 99% use the MiniMed Paradigm Revel insulin pump and 1% use other brands of insulin pumps. All insulin pump patients are referred to the diabetes education department for pre-pump, pump start, and follow-up training sessions. After the initial training sessions, many of the insulin pump patients continue to be seen by the diabetes education staff for review of insulin pump downloads and adjustment of pump settings.

The lead CDE conceived the insulin pump class after several patients on pump therapy had severe hypoglycemic episodes while driving. She identified the need for insulin pump patients to have follow-up training to review insulin pump survival skills and prevent future hypoglycemic emergencies. A database search of IM and FM patients was completed to identify the subset of patients on insulin pump therapy.

Via phone or during office visits, CDEs invited established insulin pump patients identified through the database search to attend the class. All insulin pump patients were invited to the subsequent insulin pump classes. Baseline characteristics of the patients who attended the class are described in Table 2.

To assist with class attendance, patients received a reminder call 1 day before class.

Although initial education for insulin pump therapy focuses on the basics of pump operation, the class provides more in-depth education about sick-day management, infusion site problems, and additional keys to pump success. The objectives of the class are to review insulin pump survival skills for new and experienced pump patients to prevent emergency room visits, improve glycemic control (as measured by A1C), and provide patient satisfaction.

Table 2.

Baseline Demographics of Class Participants

Baseline Demographics of Class Participants
Baseline Demographics of Class Participants

Each class takes 90 minutes. All patients who have attended the class use the MiniMed Paradigm Revel insulin pump system, so the educational materials discussed during the session focus on this product. When patients arrive for class, a CDE downloads their insulin pump. While insulin pumps are being downloaded, another CDE begins the interactive educational roundtable, which focuses on insulin pump survival skills. Topics for the roundtable include:

  • Advanced carbohydrate counting using food models

  • Battery changing and adjustment of pump settings

  • Diabetic ketoacidosis prevention

  • Troubleshooting unexplained high blood glucose levels

  • Prevention and treatment of hypoglycemia

  • Infusion site care: infusion set types and sites and infection prevention

Although these topics are discussed during the initial insulin pump training, material is covered in more depth in class, and participants can share their experiences. In addition to these discussions, patients are also given survival skills kits that contain written handouts about these topics to enforce learning. The kits also contain glucose tablets, a diabetes driver decal, and a bag of U-100 insulin syringes. After the roundtable discussion, adjustments to insulin pump settings are made as needed with CDEs and each patient individually. Patients are given a copy of their insulin pump settings.

As the class comes to an end, patients complete a post-class satisfaction survey and are given a follow-up appointment.

As the class was developed, the initial goal was to enroll six insulin pump patients every 6–8 weeks, with the first session to be held in July 2011. From July 2011 to May 2013, 10 sessions have been held, with a total of 30 participants completing the class. Although the initial goal was to have six insulin pump patients per class, actual class size has varied from two to six participants (Table 3). The outcomes data collected for the class included pre- and post-class A1C values, pre- and post-class emergency room visits, and post-class satisfaction (Tables 4, 5 and 6).

Table 3.

Insulin Pump Class Attendance

Insulin Pump Class Attendance
Insulin Pump Class Attendance

The average pre- and post-class A1C levels were calculated based on the pre- and post-class A1C levels for each participant. As demonstrated in Table 4, the overall average pre-class A1C has been 7.4%, with an overall average standard deviation of 0.44. The overall average post-class A1C has been 7.2%, with an overall average standard deviation of 0.2.

The initial assessment of emergency room visits was the number of visits in the 12 months before the class date. For the 35 patients enrolled in the class, there had been a total of four emergency visits, two of which were diabetes-related. Tracking of post-class emergency room visits is ongoing. To date, there has been only one emergency room visit by a class participant, and that visit was diabetes-related.

Participants who completed the survey in the class found the roundtable discussions, handouts, and visual aids to be helpful. The majority of participants who completed the survey (92.9%) learned at least one new skill for their insulin pump therapy. All respondents felt that what they learned will help them manage their insulin pump therapy and that their questions were answered. All survey respondents agreed to put their survival kit together and said they would recommend the class to others (Tables 5 and 6).

Although these results indicate that the class has been successful, there are several limitations. The sample size for the class is relatively small. Additionally, the timeframe for measuring the impact of the class on A1C level and number of emergency room visits has been short. Overall, participants in this class were already compliant to their insulin pump therapy regimen.

Table 4.

Differences in Participants' Pre- and Post-Class A1C Levels

Differences in Participants' Pre- and Post-Class A1C Levels
Differences in Participants' Pre- and Post-Class A1C Levels
Table 5.

Class Participant Post-Class Survey, Part A (n = 28)*

Class Participant Post-Class Survey, Part A (n = 28)*
Class Participant Post-Class Survey, Part A (n = 28)*
Table 6.

Class Participant Post-Class Survey, Part B (n = 28)*

Class Participant Post-Class Survey, Part B (n = 28)*
Class Participant Post-Class Survey, Part B (n = 28)*

CDEs are working to identify additional pump patients to enroll in the class, with the ultimate goal of having all insulin pump patients in the medical practice complete the course to improve glycemic control (as indicated by the A1C), reduce the number of diabetes-related emergency room visits, and ensure patient satisfaction with the class. The CDE team is also considering the addition of insulin pump “happy hours” on Friday afternoons as a drop-in option for patients who are unable to attend the scheduled class.

1.
Fernandez
MP
,
Marcus
AO
:
Insulin pump therapy: acceptable alternative to injection therapy
.
Postgrad Med
99
:
125
132
,
141
–144, 1996
2.
American Diabetes Association
:
Standards of medical care for patients with diabetes mellitus—2013
.
Diabetes Care
36
(
Suppl.1
):
11
66
,
2013
3.
Neithercott
T
:
Insulin pumps
.
Diabetes Forecast
65
:
50
53
,
2012
4.
Keen
H
,
Pickup
J
:
Continuous subcutaneous insulin infusion at 25 years
.
Diabetes Care
25
:
593
598
,
2002
5.
Rubin
RR
,
Peyrot
M
:
Patient-reported outcomes and diabetes technology: a systemic review of literature
.
Pediatric Endocrinol Rev
7
(
Suppl. 3
):
405
412
,
2010
6.
Jackisch
BI
,
Wagner
VM
,
Heidtmann
B
,
Lepler
R
,
Holterhus
PM
,
Kapellen
TM
,
Vogel
C
,
Rosenbauer
J
,
Holl
RW
:
Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injection (MDI) in pediatric type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years
.
Diabet Med
25
:
80
85
,
2008
7.
Hoogma
RP
,
Hammond
PJ
,
Gomis
R
,
Kerr
D
,
Bruttomesso
D
,
Bouter
KP
,
Wiefels
KJ
,
de la Calle
H
,
Scchweitzer
DH
,
Pfohl
M
,
Torlone
E
,
Krinelke
LG
,
Bolli
GB
:
Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily injections (MDI) on glycemic control and quality of life: results of the 5-nations trial
.
Diabet Med
23
:
141
147
,
2006
8.
Doyle
EA
,
Weinzimer
SA
,
Steffen
AT
,
Ahern
JA
,
Vincent
M
,
Tamborlane
WV
:
A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injection using insulin glargine
.
Diabetes Care
27
:
1554
1558
,
2004
9.
Hirsch
IB
,
Bode
BW
,
Garg
S
,
Lane
WS
,
Sussman
A
,
Hu
P
,
Santiago
OM
,
Kolaczynski
JW
:
Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII
.
Diabetes Care
28
:
533
538
,
2005
10.
Raskin
P
,
Bode
BW
,
Marks
JB
,
Hirsch
IB
,
Weinstein
RL
,
McGill
JB
,
Peterson
GE
,
Mudaliar
SR
,
Reinhardt
RR
:
Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study
.
Diabetes Care
26
:
2598
2603
,
2003
11.
Tamborlane
WV
,
Sherwin
RS
,
Genel
M
,
Feliq
P
:
Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump
.
N Engl J Med
300
:
573
578
,
1979
12.
DCCT Research Group
:
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus
.
N Engl J Med
329
:
977
986
,
1993
13.
Bode
BW
,
Davidson
PC
,
Fredrickson
LP
,
Gross
TM
,
Sabbah
HT
:
Diabetes management in the new millennium using insulin pump therapy
.
Diabetes Metab Res Rev
18
(
Suppl. 1
):
S14
S20
,
2002
14.
Nielson
S
,
Kain
D
,
Szukizik
E
,
Dhindsa
S
,
Garg
R
,
Dandona
P
:
Use of continuous subcutaneous insulin infusion pump in patients with type 2 diabetes mellitus
.
Diabetes Educ
31
:
843
848
,
2005
15.
Wittlin
S
:
Treating the spectrum of type 2 diabetes: emphasis on insulin pump therapy
.
Diabetes Educ
32
:
39S
46S
,
2006
16.
Wainstein
J
,
Metzger
M
,
Wexler
,
Cohen
J
,
Raz
I
:
The use of continuous insulin delivery systems in severely insulin-resistant patients
.
Diabetes Care
21
:
1910
1914
,
1998
17.
Scheiner
G
,
Sobel
RJ
,
Smith
DE
,
Pick
AJ
,
Kruger
D
,
King
J
,
Green
K
:
Insulin pump therapy: guidelines for successful outcomes
.
Diabetes Educ
35
(
Suppl. 2
):
29S
41S
,
2009